BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ValiRx Plc Secures Global Distribution Agreement for Diagnostic Subsidiary ValiBio with Biofield Corp. (BZET); Secures E600,000 from Sale of 10% in Subsidiary


12/15/2008 7:03:54 AM

London, UK: ValiRx subsidiary cancer diagnostics company ValiBio SA, has entered into an exclusive worldwide distribution agreement with international medical devices company Biofield Corp (“Biofield”) for its Human Papilloma Virus (HPV) diagnostic test for cervical cancer and a worldwide distribution agreement (excluding Belgium) for its Hypergenomics™ and Nucleosomics™ diagnostics products.

Under the terms of the agreement, ValiRx has also sold a 10% stake in its wholly-owned diagnostics subsidiary, ValiBio, for €600,000 in cash to Biofield with an option for Biofield to purchase an additional 15% of the Belgium-based operation.

There are over 100 different HPV viruses with certain subtypes carrying a high risk of causing cervical cancer. The global market for HPV testing is projected to be $250m in 2008, with the total available market valued at $1bn should HPV screening replace current conventional cervical cancer testing methods.

Information concerning Biofield can be found on its website - www.biofield.com

Dr Satu Vainikka ValiRx’s Chief Executive Officer said:

“This distribution agreement provides ValiBio SA with the route to the international oncology diagnostics market with a major provider of medical and health diagnostics. We are confident there is considerable market potential for these types of novel diagnostic products and expect this agreement to accelerate our revenue potential.

“Secondly, this commercial agreement also secures additional funding for our business at this important time which will be applied to the continued development of our next generation cancer diagnostics as well as to the progression of our cancer therapeutics.”

Enquiries: ValiRx plc Tel: +44 (0) 20 3008 4416 Dr. Satu Vainikka

WH Ireland Limited - NOMAD Tel: +44 (0) 161 832 2174 David Youngman / Adrian Kirk

College Hill Tel: +44 (0) 20 7866 7857 Sue Charles / Adrian Duffield /Justine Lamond valirx@collegehill.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES